151 related articles for article (PubMed ID: 34942351)
1. Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatich cholangiocarcinoma.
He K; Feng Y; An S; Liu F; Xiang G
Genomics; 2022 Jan; 114(1):241-252. PubMed ID: 34942351
[TBL] [Abstract][Full Text] [Related]
2. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
3. DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive phenotype of intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry.
Ma M; Zeng G; Tan B; Zhao G; Su Q; Zhang W; Song Y; Liang J; Xu B; Wang Z; Chen J; Hou M; Yang C; Yun J; Huang Y; Lin Y; Chen D; Han Y; DeMorrow S; Liang L; Lai J; Huang L
Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G213-G229. PubMed ID: 37366545
[TBL] [Abstract][Full Text] [Related]
4. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
5. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway.
Shen J; Zhou Y; Zhang X; Peng W; Peng C; Zhou Q; Li C; Wen T; Shi Y
Aging (Albany NY); 2019 Nov; 11(21):9280-9294. PubMed ID: 31689237
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Zhu YJ; Xu Q; Shao MY; Cao XY; Wu ZR; Chen YW; Bu H; Shi YJ
Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):464-470. PubMed ID: 31402267
[TBL] [Abstract][Full Text] [Related]
7. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
[TBL] [Abstract][Full Text] [Related]
9. MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma.
Xiong X; Sun D; Chai H; Shan W; Yu Y; Pu L; Cheng F
Biochem Biophys Res Commun; 2015 Sep; 465(2):262-9. PubMed ID: 26255969
[TBL] [Abstract][Full Text] [Related]
10. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
11. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
13. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
[TBL] [Abstract][Full Text] [Related]
14. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
15. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
[TBL] [Abstract][Full Text] [Related]
16.
Matsumori T; Kodama Y; Takai A; Shiokawa M; Nishikawa Y; Matsumoto T; Takeda H; Marui S; Okada H; Hirano T; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Marusawa H; Kageyama R; Chiba T; Seno H
Cancer Res; 2020 Dec; 80(23):5305-5316. PubMed ID: 33067264
[TBL] [Abstract][Full Text] [Related]
17. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.
Li L; Lian B; Li C; Li W; Li J; Zhang Y; He X; Li Y; Xie L
PLoS One; 2014; 9(6):e98653. PubMed ID: 24897108
[TBL] [Abstract][Full Text] [Related]
19. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
